Mary L. Disis

32.5k citations

278 papers · 14.0k indexed · 7 hit papers · h-index 60

Immunology top 0.1%
- Immunotherapy and Immune Responses 176
- Immune Cell Function and Interaction 47
- T-cell and B-cell Immunology 45
Oncology top 0.1%
- Cancer Immunotherapy and Biomarkers 82
- CAR-T cell therapy research 43
Radiology, Nuclear Medicine and Imaging top 0.5%
- Monoclonal and Polyclonal Antibodies Research 68
Cancer Research top 1%
Molecular Biology top 1%
- vaccines and immunoinformatics approaches 36
- Glycosylation and Glycoproteins Research 25

Co-authors: Keith L. Knutson Sasha E. Stanton Martin A. Cheever Kathy Schiffman Hailing Lu Vivian Goodell Sylvia Adams Lupe G. Salazar
Cited by: Immunology Oncology Radiology, Nuclear Medicine and Imaging
Journals: Proceedings of the National Academy of Sciences (1 paper)The Lancet (1 paper)JAMA (5 papers)
Partner nations: United States United Kingdom Canada

In The Last Decade

Mary L. Disis

264 papers receiving 13.8k citations

Hit Papers

7 papers align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2021 Frontiers in Immunology
2019 JAMA Oncology
2017 Journal for ImmunoTherapy of Cancer
2016 Journal for ImmunoTherapy of Cancer
2016 JAMA Oncology
2015 Journal of Clinical Oncology
2005 Cancer Immunology Immunotherapy

Peers

Countries citing papers authored by Mary L. Disis

Since Specialization

Citations

This map shows the geographic impact of Mary L. Disis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary L. Disis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary L. Disis more than expected).

Fields of papers citing papers by Mary L. Disis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary L. Disis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary L. Disis. The network helps show where Mary L. Disis may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mary L. Disis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mary L. Disis Line = papers co-authored together Mary L. Disis links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Vaccines for breast cancer prevention: Are we there yet? Molecular Aspects of Medicine ·Shaveta Vinayak,Denise L. Cecil,Mary L. Disis	2024	2
2	163 A multi-modal, pan-cancer atlas of tumor-immune states across primary and metastatic disease using a large, real-world database SHILAP Revista de lepidopterología ·Prerna Jain,Michelle M. Stein,Paul Fields,Bolesław L. Osinski,Luca Lonini,Ariane Lozac’hmeur,Rohan P. Joshi,Halla Nimeiri,Martin C. Stumpe,Kate Sasser,Catherine Igartua,Justin Guinney,Mary L. Disis	2023	0
3	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer Journal for ImmunoTherapy of Cancer ·Mary L. Disis,Sarah F. Adams,Jyoti Bajpai,Marcus O. Butler,Tyler J. Curiel,Shelley A Dodt,Laura Doherty,Leisha A. Emens,Claire F. Friedman,Margaret E. Gatti‐Mays,Melissa A. Geller,Amir A. Jazaeri,Veena S. John,Katherine C. Kurnit,John B. Liao,Haider Mahdi,Anne M. Mills,Emese Zsíros,Kunle Odunsi	2023	14
4	546 A phase I dose escalation study of STEMVAC, a multi-antigen, multi-epitope Th1 selective plasmid-based vaccine, targeting stem cell associated proteins in patients with advanced breast cancer Regular and Young Investigator Award Abstracts ·Mary L. Disis,Ying Liu,Sasha E. Stanton,William R. Gwin,Andrew L. Coveler,John B. Liao,Jennifer S. Childs,Denise L. Cecil	2022	10
5	Immunization with a Plasmid DNA Vaccine Encoding the N-Terminus of Insulin-like Growth Factor Binding Protein-2 in Advanced Ovarian Cancer Leads to High-level Type I Immune Responses Clinical Cancer Research ·Denise L. Cecil,John B. Liao,Yushe Dang,Andrew L. Coveler,Angela Shaulov Kask,Yi Yang,Jennifer S. Childs,Doreen M. Higgins,Mary L. Disis	2021	11
6	Therapeutic and Prophylactic Antitumor Activity of an Oral Inhibitor of Fucosylation in Spontaneous Mammary Cancers Molecular Cancer Therapeutics ·Mary L. Disis,Lauren R. Corulli,Ekram Gad,Marlese R. Koehnlein,Denise L. Cecil,Peter D. Senter,Shyra J. Gardai,Nicole M. Okeley	2020	15
7	The Effect of Mouse Strain, Sex, and Carcinogen Dose on Toxicity and the Development of Lung Dysplasia and Squamous Cell Carcinomas in Mice Cancer Prevention Research ·Laura Riolobos,Ekram Gad,Piper M. Treuting,Andrew E. Timms,Elliot A. Hershberg,Lauren R. Corulli,Erin Rodmaker,Mary L. Disis	2019	9
8	Immunization against HIF-1α Inhibits the Growth of Basal Mammary Tumors and Targets Mammary Stem Cells In Vivo Clinical Cancer Research ·Denise L. Cecil,Meredith Slota,Megan M. O’Meara,Benjamin C. Curtis,Ekram Gad,Yushe Dang,Daniel R. Herendeen,Lauren Rastetter,Mary L. Disis	2016	29
9	The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent Clinical Cancer Research ·Vy Phan-Lai,Yushe Dang,Ekram Gad,Jennifer S. Childs,Mary L. Disis	2015	20
10	Elimination of IL-10–Inducing T-Helper Epitopes from an IGFBP-2 Vaccine Ensures Potent Antitumor Activity Cancer Research ·Denise L. Cecil,Gregory E. Holt,Kyong Hwa Park,Ekram Gad,Lauren Rastetter,Jennifer S. Childs,Doreen M. Higgins,Mary L. Disis	2014	38
11	A Multiantigen Vaccine Targeting Neu, IGFBP-2, and IGF-IR Prevents Tumor Progression in Mice with Preinvasive Breast Disease Cancer Prevention Research ·Mary L. Disis,Ekram Gad,Daniel R. Herendeen,Vy P. Lai,Kyong Hwa Park,Denise L. Cecil,Megan M. O’Meara,Piper M. Treuting,Ronald A. Lubet	2013	59
12	Dendritic Cell–Activating Vaccine Adjuvants Differ in the Ability to Elicit Antitumor Immunity Due to an Adjuvant-Specific Induction of Immunosuppressive Cells Clinical Cancer Research ·Yushe Dang,Wolfgang Wagner,Ekram Gad,Lauren Rastetter,Carmen M. Berger,Gregory E. Holt,Mary L. Disis	2012	42
13	Concordant Release of Glycolysis Proteins into the Plasma Preceding a Diagnosis of ER+ Breast Cancer Cancer Research ·Lynn M. Amon,Sharon J. Pitteri,Christopher I. Li,Martin McIntosh,Jon J. Ladd,Mary L. Disis,Peggy L. Porter,Chee‐Hong Wong,Qing Zhang,Paul D. Lampe,Ross L. Prentice,Samir Hanash	2012	26
14	Transcriptome-Wide Studies of Merkel Cell Carcinoma and Validation of Intratumoral CD8+ Lymphocyte Invasion As an Independent Predictor of Survival Journal of Clinical Oncology ·Kelly G. Paulson,Jayasri G. Iyer,Andrew Tegeder,Renee Thibodeau,Janell M. Schelter,S Koba,David Schrama,William Simonson,Bianca D. Lemos,David R. Byrd,David M. Koelle,Denise A. Galloway,J. Helen Leonard,Margaret M. Madeleine,Zsolt B. Argényi,Mary L. Disis,Juergen C. Becker,Michele A. Cleary,Paul Nghiem	2011	224
15	VTX-2337 Is a Novel TLR8 Agonist That Activates NK Cells and Augments ADCC Clinical Cancer Research ·Hailing Lu,Gregory N. Dietsch,Maura-Ann H. Matthews,Yi Yang,Smita Ghanekar,Margaret Inokuma,Maria Suni,Vernon C. Maino,Katherine Henderson,James Jeffry Howbert,Mary L. Disis,Robert M. Hershberg	2011	134
16	The Ultimate in Cancer Chemoprevention: Cancer Vaccines Cancer Prevention Research ·Mary L. Disis	2010	4
17	Polysaccharide Krestin Is a Novel TLR2 Agonist that Mediates Inhibition of Tumor Growth via Stimulation of CD8 T Cells and NK Cells Clinical Cancer Research ·Hailing Lu,Yi Yang,Ekram Gad,Cynthia A. Wenner,Amy Chang,Emily R. Larson,Yushe Dang,Mark R. Martzen,Leanna J. Standish,Mary L. Disis	2010	125
18	Immunologic targets for breast cancer1 Breast Disease ·Mary L. Disis	2002	6
19	Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. PubMed ·Keith L. Knutson,Kathy Schiffman,Martin A. Cheever,Mary L. Disis	2002	198
20	Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. PubMed ·Mary L. Disis,Emanuel Calenoff,Graham McLaughlin,Ann Murphy,Wei Chen,Bernd Groner,Margit Jeschke,Nick Lydon,Elaine McGlynn,Robert B. Livingston	1994	390

About Mary L. Disis

Mary L. Disis is a scholar working on Immunology, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 278 papers that have together received 14.0k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (176 papers), Cancer Immunotherapy and Biomarkers (82 papers), Monoclonal and Polyclonal Antibodies Research (68 papers), Immune Cell Function and Interaction (47 papers), T-cell and B-cell Immunology (45 papers), CAR-T cell therapy research (43 papers), vaccines and immunoinformatics approaches (36 papers) and Glycosylation and Glycoproteins Research (25 papers). The work is most often cited by research in Immunology (8.5k citations), Oncology (7.8k citations) and Radiology, Nuclear Medicine and Imaging (2.3k citations). Mary L. Disis has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Keith L. Knutson, Sasha E. Stanton, Martin A. Cheever, Kathy Schiffman, Hailing Lu, Vivian Goodell, Sylvia Adams, Lupe G. Salazar, Yushe Dang and Ekram Gad. Their work appears in journals such as Proceedings of the National Academy of Sciences, The Lancet and JAMA.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact